World Antibiotic Awareness Week
Stopping one of the biggest threats to global health today.
Antimicrobial resistance (AMR) occurs naturally when microbes become immune to medication. But misuse of antibiotics in humans and animals has accelerated the problem to the point where the World Health Organization calls AMR one of the top three threats to human health.1
To keep pace, our behavior has to evolve faster than the microbes. Starting November 13, World Antibiotic Awareness Week is a time to come together and spread awareness and stress the importance of appropriate use.
When the treatment is part of the problem.
The effects of antibiotics resistance are undeniable. More people now die each year of hospital-acquired infections than of AIDS, traffic accidents and the flu combined.2
It’s not enough to hope that these newer and stronger bacteria will be fought off with newer and stronger medicine. There are only a few new antibiotics on the horizon — and the drug development process typically takes at least a decade.3
The most promising solution is to have the healthcare industry fundamentally change the way it prescribes and uses antibiotics. Without systemic changes to our mindset and behavior, antibiotic resistance will remain a major threat.
The Test Target Treat™ initiative.
Since 2013, our Test Target Treat™ initiative has helped to empower healthcare providers in their ability to make targeted treatment decisions sooner — reducing inappropriate antimicrobial use and the spread of resistance. Through educational resources, advice from leading infectious disease experts, and world-class diagnostic tools, we hope to create a shift in treatment trends, moving away from the broad over-prescription of antibiotics, which spawned the growing prevalence of serious healthcare-associated infections like MRSA, towards more targeted therapy.
Best-in-class rapid diagnostics for better decisions around antibiotics.
In this uncertain age of antibiotic resistance, it’s never been more important to know for sure which pathogen you’re treating. Alere offers best-in-class rapid diagnostic tests that help you quickly and accurately identify the source of the infection, define the most appropriate treatment strategy — and get the best possible result.
Provides the complete diagnostic picture unlike any other standalone test.
This unique test detects GDH and Toxin A/B simultaneously in less than 30 minutes. This test has been shown by multiple peer-reviewed studies from N. America, Europe and Asia to be an extremely effective tool to detect (CDI). 6,7,8,9,10,11,12
Rapid, molecular flu results in an actionable timeframe.
This molecular flu test provides accurate results in less than 15 minutes on the Alere™ i platform. Significantly faster than other molecular methods and more accurate than conventional rapid testing, Alere™ i Influenza A & B enables you to deliver actionable flu results to your patients in any setting and empowers the appropriate use of antibiotics and antivirals.
Simple. Fast. Reliable.
This important point-of-care assay helps to discriminate serious illness such as pneumonia from often self-limiting illness like acute bronchitis and other RTI.6 Alere Afinion™ CRP is a rapid in vitro diagnostic test for quantitative determination of C-reactive protein (CRP) in human blood; helping reduce diagnostic uncertainty and guiding antibiotic decision making during your patient’s visit.
A rapid and simple urine antigen test.
This test is advocated by numerous worldwide CAP guidelines including IDSA/ATS, BTS, SPILF and SEPAR. The IDSA/ATS CAP guidelines conclude that only 50% of Alere BinaxNOW® S. pneumoniae UAT positive patients can be diagnosed by conventional methods.13